公开(公告)号：WO2022023192A1

公开(公告)日：2022-02-03

申请号：PCT/EP2021/070650

申请日：2021-07-23

申请人： FUNDACIÓ INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MÈDIQUES (IMIM)

发明人： CELIÀ TERRASSA, Antoni ,  ALBANELL MESTRES, Joan ,  ROZALÉN MIRALLES, Catalina ,  PÉREZ NÚÑEZ, Iván

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K2039/585 ,  A61K39/3955 ,  A61K48/005 ,  C07K14/70567 ,  C07K16/2827 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/4704 ,  G01N2800/52 ,  G01N33/57415 ,  G01N33/6875

摘要： The present invention relates to a pharmaceutical composition comprising a LCoR activator and an immune checkpoint inhibitor (ICI), to its use in the treatment of cancer and to the use of LCoR as marker of response to immunotherapy in cancer treatment.

公开(公告)号：WO2022256437A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031818

申请日：2022-06-01

申请人： LYELL IMMUNOPHARMA, INC.

发明人： LAM, Viola ,  LYNN, Rachel Christina

IPC分类号： C12N15/113 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/725 ,  C07K14/47 ,  C07K14/705 ,  C07K16/00 ,  A61K2039/5156 ,  A61K39/001102 ,  A61K39/001188 ,  C07K14/4702 ,  C07K14/7051 ,  C07K14/70567 ,  C07K14/82 ,  C07K16/2803 ,  C07K16/3069 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C12N15/1138 ,  C12N2310/20 ,  C12N2510/00 ,  C12N5/0636

摘要： The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.